These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25465967)

  • 41. The biology of castration-resistant prostate cancer.
    Lian F; Sharma NV; Moran JD; Moreno CS
    Curr Probl Cancer; 2015; 39(1):17-28. PubMed ID: 25547388
    [No Abstract]   [Full Text] [Related]  

  • 42. First-line use of novel hormonal agents in prostate cancer: a critical appraisal.
    Raghavan D
    Clin Adv Hematol Oncol; 2018 Apr; 16(4):289-295. PubMed ID: 29742084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance.
    Jeong JH; Park SJ; Dickinson SI; Luo JL
    Mol Cell; 2017 Jan; 65(1):154-167. PubMed ID: 28041912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer.
    Mollica V; Di Nunno V; Cimadamore A; Lopez-Beltran A; Cheng L; Santoni M; Scarpelli M; Montironi R; Massari F
    Cells; 2019 Jan; 8(1):. PubMed ID: 30642011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of antiandrogen therapy for treating prostate cancer.
    Ricci F; Buzzatti G; Rubagotti A; Boccardo F
    Expert Opin Drug Saf; 2014 Nov; 13(11):1483-99. PubMed ID: 25270521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Castration-Resistant Prostate Cancer: An Algorithmic Approach.
    Stratton K; Cookson M
    Urol Clin North Am; 2017 Nov; 44(4):647-655. PubMed ID: 29107280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms leading to the development of hormone-resistant prostate cancer.
    Kasper S; Cookson MS
    Urol Clin North Am; 2006 May; 33(2):201-10, vii. PubMed ID: 16631458
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lessons from in-vivo models of castration-resistant prostate cancer.
    Lin D; Gout PW; Wang Y
    Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progress in the treatment of advanced prostate cancer.
    Sternberg CN; Petrylak DP; Madan RA; Parker C
    Am Soc Clin Oncol Educ Book; 2014; ():117-31. PubMed ID: 24857068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of castrate-resistant prostate cancer in older men.
    Ged Y; Horgan AM
    J Geriatr Oncol; 2016 Mar; 7(2):57-63. PubMed ID: 26907565
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer.
    Moul JW
    Oncology (Williston Park); 2014 Aug; 28(8):702-3, 722. PubMed ID: 25140628
    [No Abstract]   [Full Text] [Related]  

  • 53. Statin derivatives as therapeutic agents for castration-resistant prostate cancer.
    Ingersoll MA; Miller DR; Martinez O; Wakefield CB; Hsieh KC; Simha MV; Kao CL; Chen HT; Batra SK; Lin MF
    Cancer Lett; 2016 Dec; 383(1):94-105. PubMed ID: 27687622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Endocrine therapy for prostate cancer.].
    Nagaya N; Horie S
    Clin Calcium; 2018; 28(11):1527-1533. PubMed ID: 30374010
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
    Ku JY; Lee JZ; Ha HK
    Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting the androgen receptor signaling axis to reduce testosterone levels in prostate cancer: how low should we go?
    Cheng HH; Higano CS
    Oncology (Williston Park); 2014 Aug; 28(8):700-1. PubMed ID: 25140627
    [No Abstract]   [Full Text] [Related]  

  • 58. Targeting androgen-independent pathways: new chances for patients with prostate cancer?
    Cattrini C; Zanardi E; Vallome G; Cavo A; Cerbone L; Di Meglio A; Fabbroni C; Latocca MM; Rizzo F; Messina C; Rubagotti A; Barboro P; Boccardo F
    Crit Rev Oncol Hematol; 2017 Oct; 118():42-53. PubMed ID: 28917268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Alternative antiandrogen therapy for castration-resistant prostate cancer].
    Suzuki H; Utsumi T; Endo T; Kamijima S; Kamiya N
    Nihon Rinsho; 2016 May; 74 Suppl 3():589-94. PubMed ID: 27344799
    [No Abstract]   [Full Text] [Related]  

  • 60. Secondary hormonal therapy for prostate cancer: what lies on the horizon?
    Sharifi N; Dahut WL; Figg WD
    BJU Int; 2008 Feb; 101(3):271-4. PubMed ID: 17922868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.